Investor Presentaiton
US NBRX data show early signs of recovery
'000
20
15
10
5
US basal insulin NBRx count
in recent 6 months
'000
18
16
15.4
14
12
1.12.19
1.1.20
1.2.20
1.3.20
1.4.20
1.5.20
Basaglar
Lantus
Toujeo
TresibaⓇ
Levemir®
TresibaⓇ decrease of -26%
since 13 Mar 2020
7.8
5.6
4.6
2.0
US injectable GLP-1 NBRX count
in recent 6 months
8
4
O % 6 + N
10
R&D investor presentation
6
'000
2.0
12.7
1.6
2
0
1.12.19
1.1.20
1.2.20
1.3.20
1.4.20
1.5.20
9.1
1.2.
US obesity NBRx count
in recent 6 months
1.1
0.6
0.8
3.4
0.4
1.6
0.0
1.12.19
1.1.20
1.2.20 1.3.20
1.4.201
1.5.20
SaxendaⓇ
Qsymia
Contrave
Belviq
Other injectable GLP-1s
OzempicⓇ
Trulicity
Victoza®
NN inj. GLP-1
NN inj. GLP-1 decrease of
Source: US weekly 1x1 NBRX (Xponent, Diabetes 22 May 2020, Obesity 15 May 2020)
-20% since 13 Mar 2020
NN Obesity decrease of
-28% since 13 Mar 2020
novo nordiskView entire presentation